spacer
home > ebr > Winter 2008
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2008
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR
   
Text
PDF
bullet
BioFinance and Management
Maximising press coverage of anything from new product launches, to research, to company restructure is a continuous challenge for biopharmaceutical companies. Michael Willett at Bruker BioSciences outlines the various options available to get your story In the Flow  
view
download pdf
Robin Ng and Stephanie Finnegan at Goodwin Biotechnology, Inc give their advice on the benefits of attracting high-flying graduates to new roles, and the tactics involved in Winning the War of competitive recruitment within the biopharma industry  
view
download pdf
Having The Last Word in the press is a key aim for most biopharmaceutical companies. Sue Charles of College Hill examines the value of communications as a key business investment  
view
download pdf
The up-to-the-minute information, research and opportunity for discussion that the internet can provide has revolutionised the world of scientific communications, argues Sabine Duntze at b3c communications in Weaving a New Web  
view
download pdf
bullet
BioBusiness Development
Dr Achim Plum and Dr Oliver Schacht at Epigenomics AG investigate the lucrative potential of companies working together on drug development, and suggest that effective partnering allows even the smallest biotechs to have a chance at Playing in the Big Leagues  
view
download pdf
One way to get ahead of the biopharma game is through exploiting the full potential of networking within the industry; Dr Kate Rowley at Nexxus, the West of Scotland Bioscience Network, outlines its role in Partnering: the Modern Day Paradigm for Progression  
view
download pdf
The challenge of transcending national borders is one that most biopharmaceutical companies face at some stage during the drug development process. Dan Zabrowski at Roche persuades that Pursuing Partnerships is the recipe for pioneering progression  
view
download pdf
Martin Dittmer at Rockwell Automation considers The Path to Paperless Production, and concludes that electronic batch recording can transform every aspect of pharmaceutical manufacturing – from innovation to the marketplace  
view
download pdf
bullet
BioResearch and Innovation
New therapeutic paradigms rarely cause a stir comparable to that of RNAi – everyone from the new generation of biotech entrepreneurs to Wall Street has taken notice, even before its first market approval. Drug development consultant Emile Bellott investigates whether or not this excitement is justified, in A Glass Half-Full  
view
download pdf
Andreas Busjahn at HealthTwiSt predicts a potentially crucial development for biopharmaceutical R&D in Double Take, asserting that the application of molecular genetics may give the fast-diminishing use of twin studies a second wind  
view
download pdf
Advances in nanotechnology have opened up the possibility of a new era of personalised oncology, thereby providing cancer patients with more accurate diagnoses and more effective treatment. In This Time it’s Personal, Sylvia M Findlay at Frost & Sullivan assesses the communication difficulties facing this fresh approach  
view
download pdf
bullet
Discovery Technology
With an ever-increasing demand for adapted proteins, taking a synthesised approach could be the answer. Michael Liss and Ralf Wagner at GENEART examine the potential of Tailor-Made Proteins  
view
download pdf
RNA purification has always been a struggle for low-throughput laboratories due to the lack of automated platforms. In Technological Expression, Carola Shade at QIAGEN GmbH inspects a selection of brand new, innovative methods that can help to streamline the process  
view
download pdf
In Increasing 15d-PGJ2: a Novel Drug Target, Professor Ernst Wülfert at Hunter-Fleming Ltd believes the production of 15d-PGJ2 should be increased as it boasts several unique properties, despite not currently being a primary target for drug discovery and development  
view
download pdf
Consistent progress is being made in the development of sensitive and efficient assays to swiftly measure the binding of compounds. In Right on Target, Marion de Decker at Cisbio explores recent advances in what is a key element of the drug discovery process  
view
download pdf
bullet
BioDevelopment and Regulatory
Testing is one of the most costly and time-consuming aspects of a drug’s development cycle, but arguably also the most important. In Minimising Immunological Risk, Markus Wulf and Peter Trinder of Thymed GmbH evaluate the crucial parameters in the clinical and preclinical development process of vaccines, drugs and biotherapeutics  
view
download pdf
Inhalation toxicology is establishing its predominance as a method for administering an increasing range of therapies, yet the risks involved cannot be ignored and continuous development is imperative in testing systems and protocols. Paul Smith and Richard Crowley at Covance provide us with A Dose of Inspiration  
view
download pdf
In Making Your Mark, independent consultant Ray Briggs and John Allinson at Veeda Clinical Research attempt to clear up how conflicting definitions of biomarkers, together with discrepancy between the technologies available, have augmented misunderstandings in the past  
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July, and October

News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement